BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026. ...

Core Insights - Quanterix (QTRX) has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test aimed at evaluating patients with cognitive symptoms for potential Alzheimer's disease, marking a significant step in the company's efforts to provide non-invasive diagnostic solutions for Alzheimer's [1][2]. Company Developments - The 510(k) submission is indicative of strong operational execution and is a crucial milestone for Quanterix in meeting the diagnostic needs related to Alzheimer's disease [2]. - The test utilizes Simoa technology to combine five biomarkers into a single readout, offering a comprehensive view of disease biology, which is expected to enhance diagnostic interpretability, especially in early disease stages [6][9]. - The submission is supported by clinical data from over 1,800 patients across three independent cohorts, demonstrating the test's potential effectiveness [6][10]. - The multi-analyte test has previously received FDA Breakthrough Device Designation, highlighting its potential to improve diagnosis for serious conditions like Alzheimer's [8]. Market Potential - The Alzheimer's disease diagnostics and treatment market was valued at $7.72 billion in 2025 and is projected to grow at a CAGR of 9% through 2032, driven by advancements in neuroimaging technologies, monoclonal antibodies, and AI integration in diagnostics [11]. - The pending FDA clearance for Quanterix's test could significantly expand its addressable market by facilitating broader adoption of non-invasive Alzheimer's diagnostics, particularly in earlier disease stages where clinical need is high [4]. Competitive Positioning - Quanterix's integrated multi-biomarker approach differentiates it from single-analyte competitors, potentially providing pricing power and long-term clinical relevance in Alzheimer's diagnosis and treatment decisions [4][9].

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer's disease (AD). This submission represents a significant milestone in the Company's mission to provide superior, non-invasive, high-performance diagnost. ...

Core Insights - Quanterix Corporation announced the publication of a significant study in JAMA Network Open, highlighting its role in advancing healthcare through biomarker research [1] Company Overview - Quanterix Corporation is focused on transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics [1] Study Details - The study was conducted by researchers at Amsterdam UMC and followed nearly 300 individuals for up to 15 years [1] - The findings of the study are expected to have a substantial impact on the understanding of biomarkers in healthcare [1]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - European shares also experienced gains, with the eurozone's STOXX 600 up by 0.91% and other major indices like Spain's IBEX 35 and London's FTSE 100 also rising [6] - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61% and China's Shanghai Composite rising 0.92% [7] Sector Performance - Utilities sector shares increased by 1.5% on Friday, while health care stocks saw a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] Company News - Rich Sparkle Holdings Ltd shares surged 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares increased by 31% to $8.54 following the appointment of a new CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped 40% to $3.72 due to FDA identified deficiencies [9] - Pacira Biosciences Inc shares fell 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations [10] - The unemployment rate decreased to 4.4%, below expectations of 4.5% [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units [10] - Building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0, the highest since September 2025 [2][10]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite gaining approximately 150 points on Friday [1] - The Dow increased by 0.38% to 49,453.05, while the NASDAQ rose by 0.66% to 23,635.11, and the S&P 500 climbed 0.48% to 6,954.85 [1] - Utilities sector shares increased by 1.5%, while health care stocks experienced a decline of 0.5% [1] Commodity Prices - Oil prices rose by 2.7% to $59.34, gold increased by 1.2% to $4,514.50, silver surged by 6.3% to $79.895, and copper rose by 2% to $5.9150 [5] European Market Trends - European shares were generally higher, with the eurozone's STOXX 600 gaining 0.91%, Spain's IBEX 35 Index rising 0.01%, London's FTSE 100 increasing by 0.85%, Germany's DAX up by 0.43%, and France's CAC 40 rising by 1.23% [6] Asian Market Trends - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 1.61%, Hong Kong's Hang Seng Index up by 0.32%, China's Shanghai Composite rising by 0.92%, while India's BSE Sensex fell by 0.72% [7] Company-Specific Movements - Rich Sparkle Holdings Ltd saw its shares increase by 115% to $52.00 after signing a $39 million offering of 3 million ordinary shares at $13 per share [9] - Quanterix Corp shares surged by 31% to $8.54 following the appointment of Everett Cunningham as President and CEO [9] - CG Oncology Inc shares rose by 24% to $52.18 after announcing an expedited timeline for clinical trial data [9] - Aquestive Therapeutics Inc shares dropped by 40% to $3.72 due to an FDA letter identifying deficiencies [9] - Pacira Biosciences Inc shares fell by 13% to $22.70 after reporting preliminary FY25 revenue results [9] - Beta Bionics Inc shares decreased by 31% to $21.98 following preliminary fourth-quarter financial results [9] Economic Indicators - Nonfarm payrolls increased by 50,000 in December, slightly below expectations of 60,000 [10] - The unemployment rate decreased from 4.5% in November to 4.4%, below expectations [10] - Average hourly earnings rose by 0.3%, matching forecasts [10] - Housing starts declined by 4.6% to an annualized rate of 1.246 million units, while building permits fell by 0.2% to an annualized rate of 1.412 million [10] - The University of Michigan's consumer sentiment index rose to 54.0 in January, the highest since September 2025 [10]

Core Insights - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Friday [1] Company Highlights - CG Oncology Inc (NASDAQ:CGON) saw its shares rise by 21.8% to $51.05 after announcing an expedited timeline for topline data from the Phase 3 PIVOT-006 clinical trial, now expected in the first half of 2026 [1][2] - Rich Sparkle Holdings Ltd (NASDAQ:ANPA) surged 113.6% to $51.70 following a $39 million offering of 3 million ordinary shares at $13 per share [3] - NovaBay Pharmaceuticals Inc (NYSE:NBY) increased by 34.4% to $12.81 [3] - Quanterix Corp (NASDAQ:QTRX) gained 29.3% to $8.42 after naming Everett Cunningham as President and CEO, effective January 19 [3] - MoonLake Immunotherapeutics (NASDAQ:MLTX) rose 21.7% to $17.45 after receiving FDA feedback on its clinical evidence strategy for Sonelokimab in Hidradenitis Suppurativa [3] - Enliven Therapeutics Inc (NASDAQ:ELVN) increased by 21.5% to $28.24, sharing positive initial data from its Phase 1b ENABLE trial for ELVN-001 in chronic myeloid leukemia [3] - Aeva Technologies Inc (NASDAQ:AEVA) surged 21.2% to $20.47 [3] - Loandepot Inc (NYSE:LDI) rose 20.1% to $2.93 [3] - ASP Isotopes Inc (NASDAQ:ASPI) increased by 19.7% to $7.71 [3] - Allogene Therapeutics Inc (NASDAQ:ALLO) gained 19.5% to $1.78 [3] - Opendoor Technologies Inc (NASDAQ:OPEN) rose 19.2% to $7.67 following a new housing market proposal by President Donald Trump [3] - Liquidia Corp (NASDAQ:LQDA) jumped 14% to $36.22 after announcing preliminary full-year 2025 YUTREPIA net sales [3] - Vistra Corp (NYSE:VST) gained 13.1% to $170.34 after entering into 20-year power purchase agreements for zero-carbon nuclear energy to support Meta's operations [3] - Oklo Inc (NYSE:OKLO) rose 12.6% to $109.95 after announcing an agreement with Meta for a 1.2 gigawatt power campus [3] - Applied Digital Corp (NASDAQ:APLD) surged 11.8% to $35.72, reporting strong second-quarter results and advanced talks with a new hyperscaler tenant [3] - AST SpaceMobile Inc (NASDAQ:ASTS) gained 10% to $99.65 [3] - SanDisk Corp (NASDAQ:SNDK) increased by 9.6% to $366.93 [3] - Mirion Technologies Inc (NYSE:MIR) rose 9.5% to $26.56 [3] - TTM Technologies Inc (NASDAQ:TTMI) gained 9.1% to $72.94 [3] - SoundHound AI Inc (NASDAQ:SOUN) rose 8.5% to $11.96 [3] - Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) gained 8.3% to $112.64, with B. Riley Securities maintaining a Buy rating and raising the price target from $105 to $128 [3]

Compensation and Benefits - The annual base salary for the new President and CEO is set at $750,000, subject to periodic review and potential upward adjustment [5]. - The target annual performance bonus is up to 100% of the base salary, contingent on achieving specific metrics and goals established by the Company [6]. - A sign-on cash payment of $600,000 will be provided within 30 days following the start date, with repayment conditions specified [8]. - The new executive will receive 1,070,000 Time-Based RSUs and 813,750 Performance-Based RSUs, with vesting schedules based on stock price performance [9]. - Performance-Based RSUs will vest based on the volume weighted average price (VWAP) of the Company's stock reaching $10, $15, and $20 per share over specified periods [9]. Termination and Severance - In the event of termination without Cause, the executive will receive salary continuation for 12 months, an amount equal to the target bonus, and health benefits continuation [14][15][16]. - If termination occurs within a Change-in-Control period, the severance benefits will extend to 24 months, with additional health benefits and bonus payments [18][19]. - The employment is classified as "at-will," allowing either party to terminate the employment at any time for any reason [13]. - The definition of "Change-in-Control" includes events such as a person acquiring 50% or more of the company's voting securities, changes in the Board of Directors, mergers, or the sale of substantially all assets [28]. - "Good Reason" conditions include material reductions in authority, duties, or salary exceeding 10%, and significant changes in geographic work location [29][30]. Payment and Tax Considerations - Payments under the agreement may be subject to "parachute payment" rules under Section 280G, which could trigger excise taxes [32]. - If a payment is deemed an "Overpayment" or "Underpayment," the company must repay or pay the difference with interest at the applicable federal rate [35]. - The agreement aims to comply with Section 409A of the Internal Revenue Code, ensuring that payments are structured to avoid penalties [36]. - Payments classified as "non-qualified deferred compensation" will only be payable upon separation from service [37]. - If the employee is classified as a "specified employee," payments may be delayed for six months post-separation to comply with Section 409A [38]. - The company is not liable for any tax consequences related to payments under the agreement, including those under Section 409A [41][42]. Miscellaneous Provisions - The employee is not required to seek other employment to mitigate amounts payable under the agreement [43]. - Upon termination, the employee must return all company property and confidential information [44]. - The agreement constitutes the entire understanding between the parties and supersedes all prior agreements [50]. - Any portion declared illegal or unenforceable will not affect the remainder of the agreement [50]. - The agreement's provisions will survive termination to effectuate its terms [50]. - Amendments to the agreement require a written instrument signed by both parties [50]. - The company may assign its rights under the agreement without consent, but the employee cannot assign their interests without prior written consent [50]. - The agreement may be executed in counterparts, which together constitute one document [51]. - The employee acknowledges the opportunity to seek independent legal counsel before signing [51]. - The agreement is signed by the Executive Chair of Quanterix Corporation [52]. - The employee's acceptance is confirmed by their signature on the agreement [52].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - The article discusses the challenges in evaluating Quanterix (QTRX) shares following its acquisition of Akoya Biosciences, which introduced skepticism and losses into the company [1]. Group 1: Company Overview - Quanterix (QTRX) has faced difficulties in share evaluation post-acquisition of Akoya Biosciences, indicating potential concerns regarding its financial health and market perception [1]. Group 2: Investment Opportunities - The service "Value in Corporate Events" aims to provide actionable insights on major corporate events such as earnings reports, M&A, and IPOs, focusing on identifying the best investment opportunities [1].